Viroclinics-DDL’s Post

#podcast Dr. Mollie Leoni, Executive Vice President for Clinical Development of Kura Oncology discusses the company's ziftomenib program, a menin inhibitor for acute myeloid leukemia (AML). The company found that specific subtypes, such as those with NPM1 mutation or KMT2A rearrangement, were more likely to respond to the menin inhibitor. Understanding the role of menin and menin inhibitors in addressing abnormal gene expression and promoting healthy cell development opens the door to potential combination therapy, where menin inhibitors could be layered onto existing treatments for various cancers related to menin independence. #MeninInhibitors #PrecisionMedicine #BTD KuraOncology.com https://lnkd.in/gwh6p5Cw

🔬 𝐁𝐢𝐨𝐆𝐞𝐧𝐞𝐱 𝐩𝐫𝐞𝐬𝐞𝐧𝐭𝐬 𝐀𝐧𝐭𝐢-𝐁𝐫𝐠-1 𝐚𝐧𝐭𝐢𝐛𝐨𝐝𝐲 𝐟𝐨𝐫 𝐁𝐫𝐞𝐚𝐬𝐭 𝐂𝐚𝐧𝐜𝐞𝐫 𝐝𝐢𝐚𝐠𝐧𝐨𝐬𝐢𝐬. Brg1, a key gene regulator, can aid in early breast tumor detection. Our ready-to-use antibodies are top-notch, facilitating precise diagnosis and improving patient outcomes. BioGenex offers both ready-to-use (RTU) and concentrated forms of antibodies, catering to manual and automated systems. Our antibodies are best-in-class, ideal for clinicopathological diagnosis and drug discovery. Join us in the fight against breast cancer. 💪🩺 Learn More: https://hubs.la/Q027wYjD0 #BreastCancer #BioGenex #HealthcareInnovation

Genetic Basis of Relapse after GPRC5D-Targeted CAR T Cells October 12, 2023 N Engl J Med 2023; 389:1435-1437 Resistance mechanisms are being defined for CAR T cells. Tumor cells emerging after GPRC5D CAR T-cell therapy could have decreased or lost expression of the GPRC5D target through biallelic gene loss or transcriptional down-regulation. https://lnkd.in/g6737Vcr

Let’s chat about this! I would love to talk to you about how Advarra can assist in getting your oncology studies off to a great start.

OverT Bio developed a scalable gain-of-function discovery platform in human T cells to identify and prioritize the best genetic modifiers of T cell function. Dr Mat Legut will share the development and application of this discovery platform to build better cellular immunotherapies for solid tumors at #IO360nyc Learn more about the conference here - https://lnkd.in/efgEfa7t #immunooncology #cancerresearch #IO360nyc

🔬 𝐁𝐢𝐨𝐆𝐞𝐧𝐞𝐱 𝐩𝐫𝐞𝐬𝐞𝐧𝐭𝐬 𝐀𝐧𝐭𝐢-𝐁𝐫𝐠-1 𝐚𝐧𝐭𝐢𝐛𝐨𝐝𝐲 𝐟𝐨𝐫 𝐁𝐫𝐞𝐚𝐬𝐭 𝐂𝐚𝐧𝐜𝐞𝐫 𝐝𝐢𝐚𝐠𝐧𝐨𝐬𝐢𝐬. Brg1, a key gene regulator, can aid in early breast tumor detection. Our ready-to-use antibodies are top-notch, facilitating precise diagnosis and improving patient outcomes. BioGenex offers both ready-to-use (RTU) and concentrated forms of antibodies, catering to manual and automated systems. Our antibodies are best-in-class, ideal for clinicopathological diagnosis and drug discovery. Join us in the fight against breast cancer. 💪🩺 Learn More: https://hubs.la/Q027x04S0 #BreastCancer #BioGenex #HealthcareInnovation

Researchers have made a pivotal breakthrough in clinical trials, especially for those battling pancreatic cancer. A study reveals the brand of basement membrane extract (BME) used in cultivating patient-derived organoids (PDOs) does not impact drug response or gene expression.   This allows flexibility in BME selection for researchers, speeding up organoid growth and enabling faster, personalized treatment approaches. Especially significant for pancreatic cancer research, this could mean faster treatment adaptation for patients, offering a glimmer of hope against one of the most aggressive cancers. #PancreaticCancerResearch #ClinicalTrials https://lnkd.in/eazVx7Cu

Don't miss REALM's posters at AMP 2023. These posters highlight REALM's work to advance research in the field of immuno-oncology, and will be presented at the Solid Tumors poster session on Saturday, November 18. @Biocartis Poster #ST115: Robust identification of actionable gene fusions using GenMineTOP™️ (RUO), a comprehensive DNA+RNA somatic tissue profiling test Poster #ST085: The Idylla™️ MSI Test (IVD): An Automated PCR-Based System for the Determination of MSI Status as an Aid for Identification of Probable Lynch Syndrome in Colorectal Cancer Patients (in collaboration with Biocartis) https://hubs.ly/Q025DsDM0

CMIC is involved in nearly 70% of all oncology drug development in Japan, including groundbreaking genetic screening projects. As the world of science and medicine continues to evolve, CMIC is breaking new ground in genetic screening projects not only in Japan, but across the Asia-Pacific region. #GeneticScreening can make a significant impact in the oncology area by addressing unmet medical needs. These initiatives hold the potential to revolutionize the treatment and care of cancer patients. We are sharing details of two projects that hold immense promise for patients in need in the White Paper, “Genetic Screening Projects Make Japan A Rising Option For Clinical Trials.” Available now on our website: https://lnkd.in/e-URkXSg #oncology #genetics #CMIC

New! Repositioning of #antiarrhythmics for #prostatecancer treatment: a novel strategy to reprogram #cancerassociatedfibroblasts towards a tumor-suppressive phenotype ---------------- Cancer-associated fibroblasts (CAFs) play a significant role in fueling prostate cancer (PCa) progression by interacting with tumor cells. A previous gene expression analysis revealed that CAFs up-regulate genes coding for voltage-gated cation channels, as compared to normal prostate fibroblasts (NPFs). In this study, Zaffaroni Nadia, Valentina Doldi, Paolo Gandellini et al. explored the impact of antiarrhythmic drugs, known cation channel inhibitors, on the activated state of CAFs and their interaction with PCa cells. Look here👇 https://lnkd.in/dXa_Y5Yk #DrugRepositioning #Tumormicroenvironment IFO - Istituto Nazionale Tumori Regina Elena - Istituto Dermatologico San Gallicano